Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TT1GHVO)

• DTT Name: Matrix metalloproteinase (MMP) DTT Info
• Gene Name: MMP

Molecule-Related Drug & Molecule List

1 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Abametapir	DM2RX0I	Head and body lice	1G00.0	Approved	[1]

2 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BLZ-100	DMFKA4G	Glioma	2A00.0	Phase 1/2	[2]
S-3304	DMCBQTF	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[3]

13 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ABT-518	DMA2RM3	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1	[4]
BB-2983	DMYK8OG	Inflammatory bowel disease	DD72	Discontinued in Phase 1	[5]
D-1927	DM5D8JW	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1	[6]
ONO-4817	DMKRVUN	Inflammatory bowel disease	DD72	Discontinued in Phase 1	[7]
S-3536	DMZYRI3	Osteoarthritis	FA00-FA05	Discontinued in Phase 1	[8]
AG-2024	DMS7UPZ	Arthritis	FA20	Terminated	[10]
AG-3296	DMF2ME4	Solid tumour/cancer	2A00-2F9Z	Terminated	[10]
BB-1433	DMWAKC8	Arthritis	FA20	Terminated	[11]
BE-16627B	DM1SVQX	Inflammation	1A00-CA43.1	Terminated	[12]
CP-471358	DMDEPKM	Solid tumour/cancer	2A00-2F9Z	Terminated	[13]
D-5410	DMXHN6U	Rheumatoid arthritis	FA20	Terminated	[14]
D-9120	DMHNZ1P	Inflammatory bowel disease	DD72	Terminated	[15]
GI-129471	DMXVP13	Inflammation	1A00-CA43.1	Terminated	[16]

1 Preclinical Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
DFD-11	DMHXVN1	Head and body lice	1G00.0	Application submitted	[9]

1 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PNU-248686A	DM43K1D	Solid tumour/cancer	2A00-2F9Z	Investigative	[17]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [2] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [3] Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers. Int J Clin Pharmacol Ther. 2005 Jun;43(6):282-93.
• [4] Quantitative analysis of the novel anticancer drug ABT-518, a matrix metalloproteinase inhibitor, plus the screening of six metabolites in human plasma using high-performance liquid chromatography coupled with electrospray tandem mass spectrometry. J Mass Spectrom. 2004 Mar;39(3):277-88.
• [5] Matrix metalloproteinase inhibition reduces intimal hyperplasia in a porcine arteriovenous-graft model. J Vasc Surg. 2004 Feb;39(2):432-9.
• [6] Correlation of antiangiogenic and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxiamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor. Cancer Res. 1999 Mar15;59(6):1231-5.
• [7] ONO-4817, an orally active matrix metalloproteinase inhibitor, prevents lipopolysaccharide-induced proteoglycan release from the joint cartilage in guinea pigs. Inflamm Res. 2000 Apr;49(4):144-6.
• [8] CIINE Reflects Collagenase-Specific CII Breakdown in Cartilage Explant and Whole Body of Canine. Biomark Insights. 2013; 8: 77-83.
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] US patent application no. 6,858,598, Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia.
• [11] Anti-arthritic activity of hydroxamic acid-based pseudopeptide inhibitors of matrix metalloproteinases and TNF alpha processing. Inflamm Res. 1997 Jun;46(6):211-5.
• [12] Gelatinase B (MMP-9), but not its inhibitor (TIMP-1), dictates the growth rate of experimental thymic lymphoma. Int J Cancer. 1999 Aug 27;82(5):743-7.
• [13] A phase I and pharmacologic study of the matrix metalloproteinase inhibitor CP-471,358 in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2005 Feb;55(2):136-42.
• [14] US patent application no. US20080187572 A1.
• [15] WO patent application no. 2006,1139,93, Matrix metalloproteinase inhibitors of tgfss -induced subcapsular cataract formation.
• [16] Stimulation of matrix metalloproteinase-9 expression in human fibrosarcoma cells by synthetic matrix metalloproteinase inhibitors. Exp Cell Res. 2002 Apr 15;275(1):110-21.
• [17] Determination of PNU-248686A, a novel matrix metalloproteinase inhibitor, in human plasma by liquid chromatography-tandem mass spectrometry, following protein precipitation in the 96-well plate format. J Chromatogr A. 2003 Feb 14;987(1-2):249-56.